EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Entecavir Antiviral Therapy, Eryptosis, and Anemia in HBV-Related Liver Cirrhosis: Current Evidence and Potential Mechanistic Links

Saulesh Kurmangaliyeva, Kristina Baktikulova, Kairat Kurmangaliyev

Viruses · 06.11.2026 · 18 (11) · 1232

DOI: 10.3390/v18111232 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, online erschienen am 06.11.2026. Verfasst von Saulesh Kurmangaliyeva und 2 weiteren Autor:innen. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Marat Ospanov West Kazakhstan Medical University.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic hepatitis B virus (HBV) infection is a significant cause of progressive liver disease and cirrhosis, often accompanied by hematological complications, including anemia. Evidence increasingly indicates that eryptosis—the programmed death of erythrocytes—may play a role in disrupting red blood cell balance in chronic liver conditions. Eryptosis is characterized by phosphatidylserine externalization, intracellular calcium accumulation, oxidative stress, and ceramide-dependent signaling pathways. Entecavir, a highly effective antiviral medication, is used to consistently suppress HBV replication in patients with chronic hepatitis B and HBV-related cirrhosis. Entecavir-induced viral suppression is associated with improved hepatic function, biochemical markers, and clinical outcomes. However, direct evidence on the effects of HBV suppression on red blood cell survival, eryptosis, and anemia is lacking. In this review, we summarize current knowledge of eryptosis in HBV-related liver cirrhosis, focusing on its molecular mechanisms, biomarkers, and potential role in anemia. We also review the documented effects of entecavir on virological, biochemical, and hematologic parameters, and discuss possible indirect links between viral suppression, restored hepatic function, and erythrocyte homeostasis. Direct evidence linking entecavir therapy to changes in eryptosis remains scarce, underscoring the need for prospective clinical and experimental studies.

Förderung

  • Marat Ospanov West Kazakhstan Medical University

Zitieren

APA

Kurmangaliyeva, S., Baktikulova, K., & Kurmangaliyev, K. (2026). Entecavir Antiviral Therapy, Eryptosis, and Anemia in HBV-Related Liver Cirrhosis: Current Evidence and Potential Mechanistic Links. Viruses, 18(11), 1232. https://doi.org/10.3390/v18111232

Vancouver

Kurmangaliyeva S, Baktikulova K, Kurmangaliyev K. Entecavir Antiviral Therapy, Eryptosis, and Anemia in HBV-Related Liver Cirrhosis: Current Evidence and Potential Mechanistic Links. Viruses. 2026;18(11):1232. doi:10.3390/v18111232

BibTeX
@article{Kurmangaliyeva2026,
  author = {Kurmangaliyeva, Saulesh and Baktikulova, Kristina and Kurmangaliyev, Kairat},
  title = {Entecavir Antiviral Therapy, Eryptosis, and Anemia in HBV-Related Liver Cirrhosis: Current Evidence and Potential Mechanistic Links},
  journal = {Viruses},
  year = {2026},
  volume = {18},
  number = {11},
  pages = {1232},
  doi = {10.3390/v18111232}
}
Kostenlos starten →